About ZemairaWhat is Alpha-1?Patient SupportPatient SupportFor Healthcare ProfessionalsPrescribing InformationImportant Safety InformationAlready Treating Your Alpha-1?Newly diagnosed with alpha-1?Diagnosed with Chronic Lung Disease?Could it be Alpha-1?Alpha-1 Versus COPDAssessment QuestionaireQuestions to ask your doctorReceive Zemaira at no charge for up to 2 weeks.

Diagnosed with Chronic Lung Disease?

Chronic obstructive pulmonary disease (COPD) is a condition in which the airways—the tubes that carry air in and out of your lungs—are partially blocked, making it difficult to get air in and out.1 Other terms used for COPD are chronic obstructive airway disease or chronic obstructive lung disease.1 COPD can refer to emphysema, chronic bronchitis, or both.1 Most people with COPD have both chronic bronchitis and emphysema.1

The most common cause of COPD is cigarette smoking, but it can have other causes.1 One of these is a genetic disorder called alpha1-proteinase inhibitor deficiency (Alpha-1), also known as alpha1-antitrypsin deficiency (AATD).1 Alpha-1 is a shortage or absence of a protein that blocks the destructive effects of certain enzymes.1 Lack of this protein can lead to the destruction of lung tissue and cause chronic lung disease like emphysema.1

If you have been diagnosed with COPD, you may want to learn more about how to tell the difference between COPD and Alpha-1.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

  1. National Heart, Lung, and Blood Institute Diseases and Conditions Index: COPD. What is Chronic Obstructive Pulmonary Disease (COPD)? Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html. Accessed March 27, 2004.